SCHEMBL17675692

SCHEMBL17675692

Nc1cc(Cl)ccc1NC1CCOCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.45
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
KMT5B Q4FZB7 1/20 0.38
KMT5C Q86Y97 1/20 0.38
ALOX15 P16050 3/20 0.38
TSHR P16473 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PIK3CA P42336 1/20 0.38
KMT2A Q03164 1/20 0.38
OPRL1 P41146 1/20 0.38
TP53 P04637 1/20 0.37
SERPINE1 P05121 1/20 0.37
PIM1 P11309 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29860401 0.88 KDM4E (0.46) MAPK1HDAC1KDM4EGAAMAPT
SCHEMBL2731890 0.88 KDM4E (0.46) MAPK1HDAC1KDM4EGAAMAPT
SCHEMBL3792292 0.83 KDM4E (0.59) MAPK1KDM4EGAAMAPTKMT5B
SCHEMBL4801331 0.81 MAPK1 (0.45) MAPK1KDM4EGAAMAPTALOX15
SCHEMBL7185539 0.81 HSP90AA1 (0.43) MAPK1KDM4EGAAMAPTKMT5B
SCHEMBL2687892 0.81 AAK1 (0.44) MAPK1KDM4EGAAMAPTALOX15
SCHEMBL7185544 0.81 HSP90AA1 (0.43) MAPK1KDM4EGAAMAPTKMT5B
SCHEMBL29791971 0.81 AAK1 (0.44) MAPK1KDM4EGAAMAPTALOX15
SCHEMBL22725031 0.81 IKBKB (0.42) KDM4EGAAMAPTKMT5BKMT5C
SCHEMBL15693805 0.79 SERPINE1 (0.32) MAPK1HDAC1HDAC2KMT5BKMT5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107108557-B Spirocyclic indolines for the treatment and prophylaxis of Respiratory Syncytial Virus (RSV) infection 瑞威有限公司 2020-11-10 CN disclosed
EP-3204375-B1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) REVIRAL LTD (GB) 2019-02-13 EP disclosed
US-10106539-B2 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) ReViral Limited (GB) 2018-10-23 US disclosed
US-20170305908-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) ReViral Limited (GB) 2017-10-26 US disclosed
EP-3204375-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) Reviral Limited (GB) 2017-08-16 EP disclosed
WO-2016055780-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) RE:VIRAL LTD (GB) 2016-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305908-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) NR3C2, SAV1, ACE2 MAPK1 3117/4885HDAC1 667/4885HDAC2 72/4885
US-10106539-B2 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) SPTBN1, NR3C2, SPNS2 MAPK1 3045/4885HDAC1 745/4885HDAC2 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.